Vitrolife AB (publ) Interim report Q3, 2022: Actions done and synergies ahead
GOTHENBURG, Sweden, Oct. 27, 2022 /PRNewswire/ --
Third quarter
- Sales of SEK 798 (406) million, corresponding to an increase of
97% in SEK, whereof acquired growth75% and currency effect20% . Sales pro forma, adjusted for business related to Covid-19 tests, increased by5% in local currencies. - Consumables increased sales by
18% in SEK, Technologies decreased by5% in SEK, and Genetic Services contributed sales of SEK 348 million. - Including the acquisition, we have strong growth in all market regions. Americas
222% , EMEA33% , Japan Pacific88% and Asia33% in local currencies. - Organic growth in local currency, pro forma, adjusted for business related to Covid-19 tests in Americas was
7% , EMEA -8% , Japan Pacific32% and Asia10% in local currencies. - Restructuring costs for Genetic Services of SEK 29 million, whereof SEK 7 million impacted EBITDA and SEK 22 million impacted the financial net.
- Operating income before depreciation and amortisation (EBITDA) was SEK 276 (162) million, corresponding to a margin of
34.5% (40.0% ) (pro forma 33.9). EBITDA per share increased by47% . - Net income was SEK 108 (105) million, resulting in earnings per share of SEK 0.80 (0.89).
First nine months
- Sales of SEK 2,379 (1,167) million, corresponding to an increase of
104% in SEK, whereof acquired growth76% and currency effect17% . Sales pro forma, adjusted for business related to Covid-19 tests, increased by10% in local currencies. - Consumables increased sales by
23% in SEK Technologies by10% in SEK, and Genetic Services contributed sales of SEK 993 million. - Including the acquisition, we have strong growth in all market regions. Americas
238% , EMEA55% , Japan Pacific60% and Asia40% in local currencies. - Organic growth in local currency, pro forma, adjusted for business related to Covid-19 tests in Americas was
12% , EMEA3% , Japan Pacific18% and Asia16% in local currencies. - Restructuring costs for Genetic Services of SEK 31 million, whereof SEK 9 million impacted EBITDA and SEK 22 million impacted the financial net.
- Operating income before depreciation and amortisation (EBITDA) was SEK 777 (460) million, corresponding to a margin of
32.6% (39.4% ) (pro forma 33.7). EBITDA per share increased39% . - Net income was SEK 321 (310) million, resulting in earnings per share of SEK 2.36 (2.77).
Gothenburg, October 27, 2022
VITROLIFE AB (publ)
Thomas Axelsson, CEO
CONTACT:
Thomas Axelsson, CEO, phone: +46 31 721 80 01
Patrik Tolf, CFO, phone: +46 31 766 90 21
This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on October 27, 2022.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
The following files are available for download:
Interim report Q3, 2022 |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ-interim-report-q3-2022-actions-done-and-synergies-ahead-301660831.html
SOURCE Vitrolife AB (publ)